摘要
目的:比较丝裂霉素C或吡柔比星膀胱灌注预防浅表性膀胱癌术后复发的临床效果。方法:将126例浅表性膀胱癌患者随机分为2组,每组63例。其中,丝裂霉素C组用丝裂霉素C 30 mg+0.9%氯化钠注射液30 ml,膀胱灌注2 h;吡柔比星组用吡柔比星30 mg+5%葡萄糖注射液30 ml,膀胱灌注30 min;两组均术后每周1次,共8次;再每月1次,至手术后24个月。观察2组浅表性膀胱癌术后复发的情况及安全性。结果:患者均随访24个月,其中丝裂霉素C组复发率为14.3%,吡柔比星组复发率为13.7%,2组差异无统计学意义(P>0.05),且2组肿瘤进展亦无统计学意义(P>0.05)。丝裂霉素C组化学性膀胱炎的发生率为32.0%,吡柔比星组为38.5%,2组差异无统计学意义(P>0.05);2组均未见明显的全身药物反应。结论:丝裂霉素C和吡柔比星用于膀胱灌注预防浅表性膀胱癌术后复发的疗效相似,两者均可作为一线药物用于临床膀胱灌注。
Objective ：To evaluate the clinical effects of bladder instillation with mitomycin C （MMC） and pirarubicin on preventing the postoperative recurrence of superficial bladder cancer. Methods： A total of 126 patients with superficial bladder cancer were randomly divided into MMC and pirarubicin group. The MMC group were treated with 30 mg of MMC and 30 ml of 0.9% sodium chloride injection through bladder instillation for 2 hours. The pirarubicin group were treated with 30 mg of pirarubicin and 30 ml of 5% glucose injection through bladder instillation for 30 minutes. The safety and postoperative recurrence of superficial bladder cancer in two groups were observed. Results： All patients were followed up for 24 months. The recurrence rates of MMC and pirarubicin group were 14.3% and 13.7% ,the difference of which had no statistical significance and the tumour progression of two groups had no statistical significance （ P 〉 0.05 ）. The incidence rates of chemical cystitis in MMC and pirarubicin group were 32.0% and 38.5%, the difference of which had no statistical significance （ P 〉 0.05 ）. The adverse drug reactions of two groups were not obvious. Conclusions ： The clinical effects of bladder instillation with MMC and pirarubicin on preventing the postoperative recurrence of superficial bladder cancer are similar. These two drugs can be used as the preferred drug for clinical bladder instillation.
出处
《蚌埠医学院学报》
CAS
2013年第6期729-731,共3页
Journal of Bengbu Medical College
关键词
膀胱肿瘤
化学疗法
肿瘤
局部灌注
膀胱灌注
丝裂霉素C
吡柔比星
urinary bladder neoplasms
chemotherapy, cancer, regional perfusion
bladder instillation
mitomycin C
pirarubicin
